Phase II trial of intra-arterial chemotherapy using a novel lipophilic platinum derivative (SM-11355) in patients with hepatocellular carcinoma

Investigational New Drugs

Volumn 22, Issue 2, 2004, Pages 169-176

  Okusaka, Takuji ^a   Okada, Shuichi ^a   Nakanishi, Toshio ^b   Fujiyama, Shigetoshi ^c   Kubo, Yasuhiko ^d  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b HIROSHIMA UNIV SCHOOL OF MEDICINE   (Japan)

^c KUMAMOTO UNIV SCHOOL OF MEDICINE   (Japan)

^d Omuta City General Hospital   (Japan)

Author keywords

Hepatocellular carcinoma (HCC); Intra arterial chemotherapy; SM 11355

Indexed keywords

CIS [1,2 CYCLOHEXANEDIAMINE N,N' BIS(MYRISTATO)]PLATINUM; IODINATED POPPYSEED OIL; PLATINUM DERIVATIVE; SM 11355; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; ARTIFICIAL EMBOLISM; BLOOD SAMPLING; BLOOD TOXICITY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG ACCUMULATION; DRUG EFFECT; EOSINOPHILIA; FEMALE; FEVER; HIGH RISK POPULATION; HUMAN; LIPOPHILICITY; LIVER CARCINOMA; LIVER FUNCTION; LIVER TOXICITY; MALE; NAUSEA; NECROSIS; NEPHROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEINURIA; RASH; SIDE EFFECT; STOMATITIS; VOMITING;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CONFIDENCE INTERVALS; DRUGS, INVESTIGATIONAL; FEMALE; HUMANS; INFUSIONS, INTRA-ARTERIAL; LIPIDS; LIVER NEOPLASMS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; SURVIVAL RATE;

EID: 1442277082     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:DRUG.0000011793.72775.d1     Document Type: Article

References (29)

1. Kraybill WG, Harrison M, Sasaki T, Fletcher WS: Regional intra-arterial infusion of adriamycin in the treatment of cancer. Surg Gynecol Obstet 144: 335-538, 1977
2. Ansfield FJ, Ramirez G, Davis HL, Jr, Wirtanen GW, Johnson RO, Bryan GT, Manalo FB, Borden EC, Davis TE, Esmili M: Further clinical studies with intrahepatic arterial infusion with 5-fluorouracil. Cancer 36: 2413-2417, 1975
3. Buchwald H, Grage TB, Vassilopoulos PP, Rohde TD, Varco RL, Blackshear PJ: Intraarterial infusion chemotherapy for hepatic carcinoma using a totally implantable infusion pump. Cancer 45: 866-869, 1980
4. Kinami Y, Miyazaki I: The superselective and the selective one shot methods for treating inoperable cancer of the liver. Cancer 41: 1720-1727, 1978
5. Shibata J, Fujiyama S, Sato T, Kishimoto S, Fukushima S, Nakano M: Hepatic arterial injection chemotherapy with cisplatin suspended in an oily lymphographic agent for hepatocellular carcinoma. Cancer 64: 1586-1594, 1989
6. Leung WT, Shiu WC, Leung N, Chan M, Tao M, Li AK, Metreweli C: Treatment of inoperable hepatocellular carcinoma by intra-arterial lipiodol and 4′-epidoxorubicin. Cancer Chemother Pharmacol 29: 401-404, 1992
7. Ichikawa W, Togo S, Osanai T, Miyanaga T, Sawai S, Yamashita T, Kawachi Y, Nihei Z, Hirayama R, Mishima Y: Clinical study on the effect of intra-arterial injection of mitoxantrone-lipiodol emulsion for hepatocellular carcinoma. Jpn J Cancer Chemother 21: 2212-2214, 1994
8. Patt YZ, Charnsangavej C, Yoffe B, Smith R, Lawrence D, Chuang V, Carrasco H, Roh M, Chase J, Fischer H: Hepatic arterial infusion of floxuridine, leucovorin, doxorubicin, and cisplatin for hepatocellular carcinoma: effects of hepatitis B and C viral infection on drug toxicity and patient survival. J Clin Oncol 12: 1204-1211, 1994
9. Okusaka T, Okada S, Ishii H, Ikeda M, Nakasuka H, Nagahama H, Iwata R, Furukawa H, Takayasu K, Nakanishi Y, Sakamoto M, Hirohashi S, Yoshimori M: Transarterial chemotherapy with zinostatin stimalamer for hepatocellular carcinoma. Oncology 55: 276-283, 1998
10. Shimamura Y, Gunven P, Takenaka Y, Shimizu H, Shima Y, Akimoto H, Arima K, Takahashi A, Kitaya T, Matsuyama T: Combined peripheral and central chemoembolization of liver tumors. Experience with lipiodol-doxorubicin and gelatin sponge (L-TAE). Cancer 61: 238-242, 1988
11. Ohnishi K, Sugita S, Nomura F, Iida S, Tanabe Y: Arterial chemoembolization with mitomycin C microcapsules followed by transcatheter hepatic artery embolization for hepatocellular carcinoma. Am J Gastroenterol 82: 876-879, 1987
12. Aoyama K, Tsukishiro T, Okada K, Tsuchida T, Aiba N, Nambu S, Miyabayashi C, Yasuyama T, Higuchi K, Watanabe A: Evaluation of transcatheter arterial embolization with epirubicin-lipiodol emulsion for hepatocellular carcinoma. Cancer Chemother Pharmacol 31(Suppl): S55-S59, 1992
13. Okusaka T, Okada S, Ueno H, Ikeda M, Iwata R, Furukawa H, Takayasu K, Moriyama N, Sato T, Sato K: Transcatheter arterial embolization with zinostatin stimalamer for hepatocellular carcinoma. Oncology 62: 228-233, 2002
14. Kamada K, Nakanishi T, Kitamoto M, Aikata H, Kawakami Y, Ito K, Asahara T, Kajiyama G: Long-term prognosis of patients undergoing transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: comparison of cisplatin lipiodol suspension and doxorubicin hydrochloride emulsion. J Vasc Interv Radiol 12: 847-854, 2001
15. Maeda M, Uchida NA, Sasaki T: Liposoluble platinum(II) complexes with antitumor activity. Jpn J Cancer Res 77: 523-525, 1986
16. Iwai K, Maeda H, Konno T: Use of oily contrast medium for selective drug targeting to tumor: enhanced therapeutic effect and X-ray image. Cancer Res 44: 2115-2121, 1984
17. Kishimoto S, Noguchi T, Yamaoka T, Fukushima S, Takeuchi Y: In vitro release of SM-11355, cis[((1R,2R)-1,2-cyclohexanediamine-N,N′ )bis(myristato)] platinum(II) suspended in lipiodol. Biol Pharm Bull 23: 637-640, 2000
18. Fujiyama S, Shibata J, Maeda S, Tanaka M, Noumaru S, Sato K, Tomita K: Phase I clinical study of lipophilic platinum complex (SM-11355) in patients with hepatocellular carcinoma. J Gastroenterol Hepatol 13: A17, 1998 (Abstract).
19. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5: 649-655, 1982
20. Liver Cancer Study Group of Japan: Classification of primary liver cancer. Kanehara & Co, Ltd, Tokyo, 1997, p 21.
21. Okusaka T, Okada S, Ueno H, Ikeda M, Yoshimori M, Shimada K, Yamamoto J, Kosuge T, Yamasaki S, Iwata R, Furukawa H, Moriyama N, Sakamoto M, Hirohashi S: Evaluation of the therapeutic effect of transcatheter arterial embolization for hepatocellular carcinoma. Oncology 58: 293-299, 2000
22. Takayasu K, Arii S, Matsuo N, Yoshikawa M, Ryu M, Takasaki K, Sato M, Yamanaka N, Shimamura Y, Ohto M: Comparison of CT findings with resected specimens after chemoembolization with iodized oil for hepatocellular carcinoma. Am J Roentgenol 175: 699-704, 2000
23. Japan Society for Cancer Therapy: Toxicity grading criteria of the Japan Society for Cancer Therapy. J Jpn Soc Cancer Ther 32: 61-65, 1997
24. World Health Organization: WHO Handbook for Reporting Results of Cancer Treatment; Offset Publication 48. World Health Organization, Genova, 1979
25. Liver Cancer Study Group of Japan: Survey and follow-up study of primary liver cancer in Japan. Report 12. Acta Hepatologica Japonica 35: 317-330, 1997
26. Kishimoto S, Miyazawa K, Terakawa Y, Ashikari H, Ohtani A, Fukushima S, Takeuchi Y: Cytotoxicity of cis-[((1R,2R)-1,2-cyclohexanediamine-N,W)bis(myristato)]-platinum (11) suspended in lipiodol in a newly established cisplatin-resistant rat hepatoma cell line. Jpn J Cancer Res 91: 1326-1332, 2000
27. Kishimoto S, Noguchi T, Yamaoka T, Fukushima S, Takeuchi Y: Antitumor effects of a novel lipophilic platinum complex (SM-11355) against a slowly-growing rat hepatic tumor after intra-hepatic arterial administration. Biol Pharm Bull 23: 344-348, 2000
28. Aogi K, Sawamura A, Funakoshi M, Toge T: Intra-arterial infusion chemotherapy of cisplatin (CDDP)-lipiodol suspension using implantable injection port for unresectable liver cancer patients. Jpn J Cancer Chemother 20: 1485-1488, 1993
29. Sobin LH, Wittekind CH (eds): UICC TNM Classification of Malignant Tumors. 5th ed. John Wiley & Sons, Inc, New York, NY, 1997, pp 74-77